[1] Li ZQ, Hu ML, Zhang C, et al. Efficacy and safety of tacrolimus vs. cyclophosphamide for idiopathic membranous nephropathy:A meta-analysis of Chinese adults[J]. J Huazhong Univ Sci Technolog Med Sci, 2015, 35(5):623-628.[2] Ramachandran R, Hn HK, Kumar V, et al. Tacrolimus combined with corticosteroids versus modified ponticelli regimen in treatment of idiopathic membranous nephropathy:Randomized control trial[J]. Nephrology (Carlton), 2016, 21(2):139-146.[3] Santosh T, Liu H, Liu B. Effect of tacrolimus in idiopathic membranous nephropathy:a meta-analysis[J]. Chin Med J, 2014, 127(14):2693-2699.[4] Chen W, Liu Q, Liao Y, et al. Outcomes of tacrolimus therapy in adults with refractory membranous nephrotic syndrome:a prospective, multicenter clinical trial[J]. Am J Med Sci, 2013, 345(2):81-87.[5] Chen M, Li H, Li XY, et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy:a multicenter randomized controlled trial[J]. Am J Med Sci, 2010, 339(3):233-238.[6] Yuan H, Liu N, Sun GD, et al. Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome[J]. Pharmacology, 2013, 91(5/6):259-266.[7] Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009, 361(1):11-21.[8] Qin W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy[J]. J Am Soc Nephrol, 2011, 22(6):1137-1143.[9] Cravedi P, Ruggenenti P, Remuzzi G. Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy[J]. J Am Soc Nephrol, 2011, 22(8):1400-1402.[10] Wang C, Lu H, Yang C, et al. Progress on the M-type phospholipase A2 receptor in idiopathic membranous nephropathy[J]. Clin Med J, 2014, 127(10):1960-1963.[11] Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus:a further update of its use in the management of organ transplantation[J]. Drugs, 2003, 63(12):1247-1297.[12] Dähnrich C, Komorowski L, Probst C, et al. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy[J]. Clin Chim Acta, 2013, 421:213-218.doi:10.1016/j.cca.2013.03.015.[13] Bech AP, Hofstra JM, Brenchley PE, et al. Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy[J]. Clin J Am Soc Nephrol, 2014, 9(8):1386-1392.[14] Segarra-Medrano A, Jatem-Escalante E, Carnicer-Cáceres C, et al. Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus[J]. Nefrologia, 2014, 34(4):491-497.[15] 刘园园,郭晓林,金晶兰.激素联合聚乙二醇干扰素α-2b治疗肾病综合征合并失代偿期丙型肝炎肝硬化1例报告[J].临床肝胆病杂志,2014,30(1):72-73. |